{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:34:16Z","timestamp":1788986056339,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Preliminary data suggest that the effectiveness of dalbavancin may be similar to current standard-of-care (SoC) treatment options for osteomyelitis with an advantageous dosing schedule.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, observational cohort study of adult patients diagnosed with osteomyelitis. Patients were matched 1:2 to dalbavancin (administered as 2 doses separated by 1 week) or SoC treatment for osteomyelitis according to the Charlson Comorbidity Index, site of infection, and causative pathogen. The primary objective was to determine the incidence of treatment failure after a 1-year follow-up period. Secondary objectives included hospital length of stay (LOS), infection-related 1-year readmission rates, and treatment-related adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 132 patients received dalbavancin (n\u2005=\u200542) or SoC (n\u2005=\u200590). Baseline characteristics, including rates of surgical intervention, were similar between the 2 treatment groups. Treatment failure was similar between those who received dalbavancin and SoC (21.4% vs 23.3%; P\u2005=\u2005.81). Patients who received dalbavancin had a shorter hospital LOS (5.2 days vs 7.2 days; P\u2005=\u2005.01). There was no difference in the rates of infection-related readmission between the dalbavancin and the SoC group (31% vs 31.1%; P\u2005=\u2005.99). There were numerically fewer adverse events in the dalbavancin group compared with the SoC group (21.4% vs 36.7%; P\u2005=\u2005.08). Peripherally inserted central catheter line\u2013related complications were reported in 17.8% of patients in the SoC group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dalbavancin administered as a 2-dose regimen is a safe and effective option for the treatment of osteomyelitis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab589","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:11:21Z","timestamp":1639869081000},"source":"Crossref","is-referenced-by-count":25,"title":["Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-9321","authenticated-orcid":false,"given":"Alexander R","family":"Cain","sequence":"first","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-5345","authenticated-orcid":false,"given":"Derek N","family":"Bremmer","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8543-4972","authenticated-orcid":false,"given":"Dustin R","family":"Carr","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L","family":"Walsh","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-7490","authenticated-orcid":false,"given":"Matthew A","family":"Moffa","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-438X","authenticated-orcid":false,"given":"Nathan R","family":"Shively","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L","family":"Trienski","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"2022012017253388000_CIT0001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection.","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2022012017253388000_CIT0002","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults.","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022012017253388000_CIT0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections.","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022012017253388000_CIT0004","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults.","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022012017253388000_CIT0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022012017253388000_CIT0006","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis.","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"2022012017253388000_CIT0007","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jinf.2010.03.006","article-title":"The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens.","volume":"60","author":"Sheehy","year":"2010","journal-title":"J Infect"},{"key":"2022012017253388000_CIT0008","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in-vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2022012017253388000_CIT0009","volume-title":"Dalbavancin. Package Insert","year":"2014"},{"key":"2022012017253388000_CIT0010","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012017253388000_CIT0011","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety.","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022012017253388000_CIT0012","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2012.07.003","article-title":"Peripherally inserted central catheters and other intravascular devices: how safe are they for hemodialysis patients?","volume":"60","author":"Shingarev","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2022012017253388000_CIT0013","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bmjqs-2018-008726","article-title":"Patient-reported complications related to peripherally inserted central catheters: a multicenter prospective cohort study.","volume":"28","author":"Krein","year":"2019","journal-title":"BMJ Qual Saf"},{"key":"2022012017253388000_CIT0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13756-016-0161-0","article-title":"Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study.","volume":"6","author":"Grau","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022012017253388000_CIT0015","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/jac\/dkaa188","article-title":"Dalbavancin for the management of osteomyelitis: a major step forward?","volume":"75","author":"Almangour","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab589\/41819195\/ofab589.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/2\/ofab589\/42248122\/ofab589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/2\/ofab589\/42248122\/ofab589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T17:39:38Z","timestamp":1642700378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab589\/6469809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab589","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,18]]},"article-number":"ofab589"}}